$Amazing $Biotech & $olid $Microcap $tocks

[ash111]

ONCS great DD.also important to note that Punit Dhillon,Co-Founder & CEO sounds pretty confident about Upcoming data : Punit Dhillon? @PunitDhillon Oct 12

"Also, preclinical data will show PIIM construct as true differentiator in I-O, by expressing multiple gene targets on one vector $ONCS"
https://twitter.com/PunitDhillon?s=09

Market cap is just $27m (and very reasonable even w/fully diluted shares), very low debt and very solid Assets/Liabilities ratio of 5. had $16.1m cash (last 10Q) and Cash burn rate about $1.6/month which is reasonable too.

Management members have solid resume and recently appointed Dr. Annalisa M. Jenkins as a director on the Company’s Board of Directors and as a member of the Audit Committee and Nominating & Corporate Governance Committee of the Company’s Board of Directors, in each case effective as of September 5, 2017.  "She also served as Executive Vice President Global Development and Medical Affairs from 2011 to 2013 at Merck Serono" http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12265655

Potential is enormous. "Beyond that, if successful with melanoma, OncoSec and Merck may expand the combination therapy to other cancers Keytruda is already approved to treat. These include head and neck cancer and lung cancer, with the same regulatory pathway of conditional approval after a registrational phase II trial. Success with Keytruda could also open the door to Opdivo and collaborating with Bristol-Myers".

"There are about 15,700 patients receiving anti-PD-1 therapy for melanoma, of which about 10,200 of them are nonresponders. If ImmunoPulse IL-12 can show a 30% response rate for nonresponders, that would increase the addressable market by about 3,060 patients. At a cost of $150,000 per year, that translates to revenues of about $460 million annually. Considering that, the fact OncoSec has a market cap of only $24 million means if the registrational phase II succeeds, shares could be quickly revalued higher".
https://www.gurufocus.com/news/518583/merck-collaborates-with-oncosec-medical-to-unlock-untapped-market-for-keytruda-

We might have same MRNS type potential mover. imo